Skip to main content
ENDO 2026 Main banner

Carmelo Nucera, MD, PhD

Associate Professor
BIDMC/Harvard Medical School, Leader: Human Thyroid Cancers Preclinical and Translational Research
Boston, MA, United States

Carmelo Nucera, M.D./Ph.D., is an Associate Professor at Harvard Medical School in the Cancer Center at the Beth Israel Deaconess Medical Center (BIDMC). By training, he is an endocrinologist with medical education in Italy, and is a Physician-Scientist.
Dr. Nucera is the principal investigator (leader) of the human Thyroid Cancers Preclinical and Translational Research at BIDMC/Harvard Medical School.
He was trained during his Post-Doctoral Research Fellowship at Massachusetts General Hospital. Dr. Nucera has donated a great deal of time and enthusiasm to the research community, e.g. at the American Thyroid Association (ATA), serving as Chair of the Research Committee, member of the Website and Program committees. In addition, he also became Chair of the Diversity, Equity and Inclusion (DEI) Committee at the ATA. Dr. Nucera has been the recipient of many international awards (Guido Berlucchi , ATA Van Meter award, ITOG Gagel discovery award, Harold Dvorak award, and recently the BIDMC Elevator Pitch) and is serving the research community on different advisory committees: the ATA and International Thyroid Oncology Group (ITOG) (Chair of the Website Committee, liaison leader of the Correlative Science committee, and member of the Board Of Directors).
He is a Principal Investigator of thyroid cancer federal research grants (NIH, DOD), invited presenter at international medical conferences. He has assisted NIH, DOD, and numerous international journals as peer-reviewer, or as associate editor. He is mentoring, tutoring and teaching. He was the recipient of a ThyCa Survivors’ Thyroid Cancer Award at the ATA. He is compassionate and aims to pursue his interest in endocrine research, engaging in basic and translational research. His research program uses a multidisciplinary approach to provide new insights into the role of thyroid cancer microenvironment, develop combined targeted therapies overcoming drug resistance, and identify novel biomarkers for early diagnosis and prognosis of aggressive thyroid cancers.

Disclosure information not submitted.

Presentation(s):